The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis.

Diabetes Obes MetabJun 15, 2026 (epub)
Clinical ResearchEndocrinologyGastroenterologyOpen access

Naseem Eisa, Mira Khoury

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of semaglutide 2.4 mg on quality of life in adults with overweight or obesity. Analyzing data from four randomized placebo-controlled trials involving 4182 participants, the study found that semaglutide improved SF-36v2 Physical Functioning scores by a mean difference of 1.71 points compared to placebo, though this was below the clinically meaningful threshold.

Key findings

  • Semaglutide improved SF-36v2 Physical Functioning by 1.71 points compared to placebo.
  • The improvement in physical functioning was below the meaningful change threshold of 3.7 points.
  • Effects on quality of life were larger in participants without type 2 diabetes.
  • Two trials reported IWQOL-Lite-CT outcomes, showing similar modest improvements.

Why it matters

Understanding the effects of semaglutide on quality of life is crucial for clinicians managing patients with obesity, as it informs expectations regarding treatment outcomes and patient-reported benefits.

Source

PubMed · PMID 42297754Free full text on PubMed Central

Published in Diabetes Obes Metab. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.